Basimglurant

Phase 3Small molecule

Roche

Basimglurant is one of 10 small molecule programs targeting Trigeminal Neuralgia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Trigeminal NeuralgiaActive, not recruiting

Trigeminal NeuralgiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Trigeminal Neuralgia

#DrugCompanyPhaseTrials

Tegretol

Novartis

Approved

6 2

Trileptal

Novartis

Approved

3 3

Xylocaine

MMEDRx USA, Inc.

Approved

1 4

Lamictal

GGlaxo Dba Glaxosmithkline

Approved

1 5

Intuniv

PPromius Pharma, LLC

Approved

—6

Onabotulinumtoxina 100 UNT

SStanford University

Phase 3

1 7

Basimglurant

Roche

Phase 3

1 8

Vimpat

UCB

Preclinical

1 9

Alloex

TThe Foundation for Orthopaedics and Regenerative Medicine

Phase 1

1 10

Cerebyx

LLupin Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2/3Active, not recruiting

Trigeminal Neuralgia

NCT05217628

Clinical

Trials by Indication[1]

Trigeminal Neuralgia1 trial

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

Active, not recruiting·NNoema Pharma AG·Phase 2/3·NCT05217628·166 enrolled

Major Depressive Disorder1 trial

A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

Completed· Roche logo

Roche·Phase 1·NCT02433093·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Basimglurant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Basimglurant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Basimglurant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Basimglurant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Trigeminal Neuralgia1 trial

Major Depressive Disorder1 trial

References

Drug Info

Quick Facts

Related News